“Increasing Focus on Precision Medicine and The Development of Targeted Therapies”
- One prominent trend in the evolution of the acute intermittent porphyria market is the increasing focus on precision medicine and the development of targeted therapies to address the underlying genetic causes of the disease
- These advancements are transforming the management of AIP by enabling early diagnosis, reducing the frequency of acute attacks, and improving long-term patient outcomes through personalized treatment approaches
- For instance, RNA interference (RNAi) therapies such as Givlaari (givosiran) have demonstrated significant potential in reducing porphyrin precursor levels, thereby minimizing the frequency and severity of AIP attacks. In addition, emerging gene therapies targeting the root cause of the enzyme deficiency offer the possibility of a one-time curative approach
- These innovations are reshaping the AIP treatment landscape, improving the quality of life for patients, and driving the demand for advanced diagnostic tools and targeted therapies
